CGCT 2023
6month9 - 10On [date], guided by the National Biopharmaceutical Technology Innovation Center, the Professional Committee on Medical Engineering Transformation and Health Industry Integration of the Chinese Research Hospital Association, Boteng Biotechnology, and Bao'ao ValleyBioValley,BioBAYCo-hosted the 3rd China Gene and Cell Therapy Qingliu ForumCGCT 2023) was successfully held in Suzhou.
This conference continues to focus on the forefront of academic research in cellular and gene immunotherapy in China, standing at a higher level and with a broader perspective. It delves into new achievements and breakthroughs in fields such as cell therapy, gene therapy, nucleic acid drugs, and oncolytic viruses, for a comprehensive discussion.CGTThe new era of the field. This forum has invited leaders in the biopharmaceutical industry and cliniciansIP addressJoined by scientific research representatives, well-known capital providers, and international guests from Japan, South Korea, and the United States to discussCGTField development, number of participants800+.
As part of this year's conference “CGTCo-venue with the Oncolytic Virus Special Session ” and Strategic Partner, Frost & Sullivan (Frost & SullivanLiu Weiqi, Consulting Director of the Healthcare Business Unit at Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan'), attended the conference and delivered a speech on 'The Current Development Status and Future Trends of the Oncolytic Virus Drug Industry'.
Consulting Director, Healthcare Business Unit, Frost & Sullivan Greater China Liu Weiqi
Liu Weiqi said, Tumors have become one of the most serious diseases threatening human health, with a continuous increase in incidence and mortality rates globally and in China. Current traditional tumor treatment methods still have many unmet clinical needs. Ongoing development of oncolytic virus drugs has basically covered solid tumors in high-incidence cases. The global anti-tumor drug market is currently dominated by targeted drugs, with tumor immunotherapy showing significant therapeutic advantages. As technology continues to mature, tumor immunotherapy is expected to occupy a major share of the anti-tumor drug market in the future. The rapid expansion of the tumor immunology market will also promote the development of oncolytic virus drugs.
Oncolytic virus therapy for tumors has the potential of high lethality efficiency, good targeting, high safety, and few adverse reactions, and has become a new hot topic in the field of tumor treatment research. Oncolytic virus therapy has gone through an early exploration of natural viruses, and later advancements in genetic engineering technology have enhanced the targeting and immunosensitization capabilities of oncolytic virus drugs, promoting their rapid development. Liu Weiqi pointed out that driven by factors such as advancements in genetic engineering technology, an increase in the number of tumor patients, favorable policies, and combination therapies, the market for oncolytic virus drugs has significant growth potential.
Looking at the progress and development trends of oncolytic virus drug research and development, Global and Chinese investigational oncology drugs mainly target melanoma for clinical trials. The types of viruses are diverse globally, with herpes simplex virus being the predominant type in China; Most of the globally and locally developed oncolytic virus drugs are in the early stages, mainly focusing on combination therapy. It is expected that more oncolytic virus combination therapies will be applied in the future.
"Believing that the future market for oncolytic virus drugs will develop in the direction of expanding clinical application scope, diversifying routes of administration, and offering more solutions to drug resistance," said Liu Weiqi.
Finally, Liu Weiqi briefly introduced to the audience present the upcoming 'Blue Book on the Development of China's Oncolytic Virus Industry' by Frost & Sullivan. The blue book The aim is to conduct an in-depth analysis of the current development status, competitive landscape, capital enthusiasm, R&D barriers, etc., of the oncolytic virus industry. This includes tracking the development context of the industry and technology, exploring its potential for growth, analyzing the driving factors behind market development, and hoping to sort out the current industrial situation and reflect future growth trends for participants in the oncolytic virus industry.
About Frost & Sullivan's Healthcare Practice
The Healthcare Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, Frost & Sullivan Healthcare has unique core advantages in healthcare industry investment and financing services. Frost & Sullivan Healthcare has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions, offering one-stop solutions for enterprises in specialized fields such as pharmaceuticals and medical devices. Our services have received wide attention from investors.
